MRRS adds "Global Non-Hematological Cancers Market to 2021 – Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of global cancer prevalence. The key cancer indications of this report, namely breast, colorectal, lung and prostate cancer, constitute approximately 51% of global cancer prevalence.

The risk of cancer increases greatly in patients over the age of 65. As populations are projected to increase, with aging and increasing incidence of obesity, the prevalence of cancer as a genetic disease is only anticipated to increase, thereby acting as a driver for revenue growth. Typically, chemotherapy has curative or palliative uses depending on whether the patient’s tumors are resectable or unresectable, respectively; however, use of chemotherapies is often reliant on performance status, which is lacking in many cancer patients.

There has been a shift towards developing targeted therapies, which by their nature have less toxicity associated with their use and as a result can be administered to greater numbers of cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Table of Contents
3 Key Marketed Products 32
3.1 Overview 32
3.2 Avastin (bevacizumab) 33
3.3 Herceptin (trastuzumab) 35
3.4 Alimta (pemetrexed) 37
3.5 Zytiga (abiraterone acetate) 38
3.6 Xtandi (enzalutamide) 39
3.7 Perjeta (pertuzumab) 40
3.8 Tarceva (erlotinib hydrochloride) 41
3.9 Yervoy (ipilimumab) 43
3.10 Conclusion 44
4 Pipeline Landscape Assessment 45
4.1 Overview 45
4.2 Pipeline Development Landscape 45
4.3 Molecular Targets in the Pipeline 49
4.4 Clinical Trials 52
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 53
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 56
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 60
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 64
4.4.5 Conclusion 68
4.5 Assessment of Key Pipeline Products 69
4.5.1 Neratinib - Puma Biotechnology 69
4.5.2 AZD-4736 - AstraZeneca 70
4.5.3 LY2835219 - Eli Lilly 71
4.5.4 LEE-011 - Novartis 72
4.5.5 JNJ-56021927 - Johnson & Johnson 73
4.5.6 Tremelimumab - AstraZeneca 74
4.5.7 Margetuximab - Macrogenics 75
4.5.8 Conclusion 76
5 Multi-scenario Market Forecast to 2021 77......

List of Tables and Figures 
Table 1: Oncology, Global, Symptoms of Most Prevalent Non-hematological Cancers, 2015 10
Table 2: Complications Associated with Breast, Colorectal, Lung and Prostate Cancers 21
Table 3: Oncology, Global, Epidemiology of Most Prevalent Non-hematological Cancers, 2015 21
Table 4: Optimal and Actual Radiation Therapy Usage Rates, US, 1995-2000 27
Table 5: Optimal and Actual Chemotherapy Usage Rates, Australia, 2010 29
Table 6: Oncology Therapeutics Market, Global, Approved Indications for Avastin, 2015 34
Table 7: Oncology Therapeutics Market, Global, Approved Indications for Herceptin, 2015 36
Table 8: Oncology Therapeutics Market, Global, Approved Indications for Alimta, 2015 37
Table 9: Oncology Therapeutics Market, Global, Approved Indications for Zytiga, 2015 38
Table 10: Oncology Therapeutics Market, Global, Approved Indications for Xtandi, 2015 39
Table 11: Oncology Therapeutics Market, Global, Approved Indications for Perjeta, 2015 40
Table 12: Oncology Therapeutics Market, Global, Approved Indications for Tarceva, 2015 42
Table 13: Oncology Therapeutics Market, Global, Approved Indications for Yervoy, 2015 43
Table 14: Oncology, Global, Market Size ($bn), 2014-2021 78
Table 15: Oncology, Global, Usage of Generics Across Key Indications, 2016 81
Table 16: Oncology Therapeutics Market, Global, Forecast Revenues by Company, 2014-2021 87.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/global-non-hematological-cancers-market-to-2021-strong-growth-driven-by-increased-uptake-of-low-toxicity-targeted-treatments-and-versatile-biologics

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/